Overlapping gene expression profiles indicative of antigen processing and the interferon pathway characterize inflammatory fibrotic skin diseases

Expert Review of Clinical Immunology

Volumn 10, Issue 2, 2014, Pages 231-241

  Limpers, Annelies ^a   Van Royen Kerkhof, Annet ^a   Van Roon, Joel AG ^a   Radstake, TimothyRDJ ^a   Broen, Jasper C A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

eosinophilic fasciitis; fibrosis; lichen sclerosus; localized scleroderma; skin; systemic sclerosis

Indexed keywords

INTERFERON; LITHIUM ION;

ANTIGEN PRESENTATION; DERMATOLOGIST; DERMATOMYOSITIS; EOSINOPHILIC FASCIITIS; FIBROBLAST; GENE EXPRESSION PROFILING; HUMAN; INFLAMMATORY FIBROTIC SKIN DISEASE; INTERFERON PRODUCTION; LICHEN SCLEROSUS ET ATROPHICUS; LOCALIZED SCLERODERMA; NONHUMAN; OVERLAPPING GENE; PHENOTYPE; REVIEW; RHEUMATOLOGY; SKIN DISEASE; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

ANIMALS; ANTIGEN PRESENTATION; EOSINOPHILS; FIBROSIS; HUMANS; INFLAMMATION; INTERFERONS; MICROARRAY ANALYSIS; SKIN; SKIN DISEASES;

EID: 84893053085     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.872561     Document Type: Review

References (60)

1. Fett N, Werth VP. Update on morphea: Part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2011;64(2):217-28
2. Canady J, Karrer S, Fleck M, Bosserhoff AK. Fibrosing connective tissue disorders of the skin: Molecular similarities and distinctions. J Dermatol Sci 2013;70(3): 151-8
3. Ghoreishi M, Vera KC, Dutz JP. Type 1 IFN-induced protein MxA and plasmacytoid dendritic cells in lesions of morphea. Exp Dermatol 2012;21(6): 417-19
4. Kurzinski K, Torok KS. Cytokine profiles in localized scleroderma and relationship to clinical features. Cytokine 2011;55(2): 157-64
5. Takehara K, Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology (Oxford) 2005;44(3):274-9
6. Viallard JF, Taupin JL, Ranchin V, et al. Analysis of leukemia inhibitory factor, type 1 and type 2 cytokine production in patients with eosinophilic fasciitis. J Rheumatol 2001;28(1):75-80
7. Villasenor-Park J, Ortega-Loayza AG. Microarray technique, analysis, and applications in dermatology. J Invest Dermatol 2013;133(4):e7
8. Huang dW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4(1):44-57
9. Vonk MC, Broers B, Heijdra YF, et al. Systemic sclerosis and its pulmonary complications in The Netherlands: An epidemiological study. Ann Rheum Dis 2009;68(6):961-5
10. Wollheim FA. Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford) 2005;44(10):1212-16
11. Milano A, Pendergrass SA, Sargent JL, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 2008;3(7):e2696
12. Dieude P, Guedj M, Wipff J, et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 2009; 60(8):2472-9
13. Rueda B, Broen J, Simeon C, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 2009;18(11): 2071-7
14. Whitfield ML, Finlay DR, Murray JI, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003;100(21): 12319-24
15. Gardner H, Shearstone JR, Bandaru R, et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006;54(6):1961-73
16. Pendergrass SA, Lemaire R, Francis IP, et al. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol 2012;132(5):1363-73
17. Chung L, Fiorentino DF, Benbarak MJ, et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 2009;60(2):584-91
18. Hinchcliff M, Huang CC, Ishida W, et al. Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro. Clin Exp Rheumatol 2012;30(2 Suppl 71):S86-96
19. Zhou L, Askew D, Wu C, Gilliam AC. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 2007; 127(2):281-92
20. Greenblatt MB, Sargent JL, Farina G, et al. Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol 2012;180(3):1080-94
21. Wong D, Kea B, Pesich R, et al. Interferon and biologic signatures in dermatomyositis skin: Specificity and heterogeneity across diseases. PLoS ONE 2012;7(1):e29161
22. Higgs BW, Liu Z, White B, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011;70(11): 2029-36
23. Higgs BW, Zhu W, Richman L, et al. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients. Int J Rheum Dis 2012;15(1):25-35
24. Zhou X, Tan FK, Xiong M, et al. Monozygotic twins clinically discordant for scleroderma show concordance for fibroblast gene expression profiles. Arthritis Rheum 2005;52(10):3305-14
25. Zhou X, Tan FK, Xiong M, et al. Systemic sclerosis (scleroderma): Specific autoantigen genes are selectively overexpressed in scleroderma fibroblasts. J Immunol 2001; 167(12):7126-33
26. Fuzii HT, Yoshikawa GT, Junta CM, et al. Affected and non-Affected skin fibroblasts from systemic sclerosis patients share a gene expression profile deviated from the one observed in healthy individuals. Clin Exp Rheumatol 2008;26(5):866-74
27. Tan FK, Hildebrand BA, Lester MS, et al. Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. Arthritis Rheum 2005;52(3):865-76
28. Gambichler T, Skrygan M, Labanski AA, et al. Significantly increased CCL5/ RANTES and CCR7 mRNA levels in localized scleroderma. Regul Pept 2011; 170(1-3):4-6
29. Duncan MR, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991;97(4):686-92
30. Huang KW, Chen XH. Pathology of eosinophilic fasciitis and its relation to polymyositis. Can J Neurol Sci 1987;14(4): 632-7
31. Lakhanpal S, Ginsburg WW, Michet CJ, et al. Eosinophilic fasciitis: Clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 1988;17(4):221-31
32. Lebeaux D, Frances C, Barete S, et al. Eosinophilic fasciitis (Shulman disease): New insights into the therapeutic management from a series of 34 patients. Rheumatology (Oxford) 2012;51(3):557-61
33. Arican O, Ciralik H, Sasmaz S. Unsuccessful treatment of extragenital lichen sclerosus with topical 1% pimecrolimus cream. J Dermatol 2004;31(12):1014-17
34. Thomas RH, Ridley CM, McGibbon DH, Black MM. Anogenital lichen sclerosus in women. J R Soc Med 1996;89(12):694-8
35. Terlou A, Santegoets LA, van der Meijden WI, et al. An autoimmune phenotype in vulvar lichen sclerosus and lichen planus: A Th1 response and high levels of microRNA-155. J Invest Dermatol 2012;132(3 Pt 1):658-66
36. O'Connell RM, Kahn D, Gibson WS, et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010;33(4): 607-19
37. Rai D, Kim SW, McKeller MR, et al. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci USA 2010;107(7):3111-16
38. Edmonds E, Barton G, Buisson S, et al. Gene expression profiling in male genital lichen sclerosus. Int J Exp Pathol 2011; 92(5):320-5
39. Pugliese JM, Morey AF, Peterson AC. Lichen sclerosus: Review of the literature and current recommendations for management. J Urol 2007;178(6):2268-76
40. Bielsa M I. Update on the classification and treatment of localized scleroderma. Actas Dermosifiliogr 2013;104(8):654-66
41. Azurdia RM, Luzzi GA, Byren I, et al. Lichen sclerosus in adult men: A study of HLA associations and susceptibility to autoimmune disease. Br J Dermatol 1999; 140(1):79-83
42. Gao XH, Barnardo MC, Winsey S, et al. The association between HLA DR, DQ antigens, and vulval lichen sclerosus in the UK: HLA DRB112 and its associated DRB112/DQB10301/04/09/010 haplotype confers susceptibility to vulval lichen sclerosus, and HLA DRB10301/04 and its associated DRB10301/04/DQB10201/02/03 haplotype protects from vulval lichen sclerosus. J Invest Dermatol 2005;125(5): 895-9
43. Kuhnl P, Sibrowski W, Kalmar G, et al. HLA-Antigen frequencies in patients with progressive systemic sclerosis and morphea. Beitr Infusionsther 1990;26:287-9
44. Farrell AM, Marren PM, Wojnarowska F. Genital lichen sclerosus associated with morphoea or systemic sclerosis: Clinical and HLA characteristics. Br J Dermatol 2000; 143(3):598-603
45. Lutz V, Frances C, Bessis D, et al. High frequency of genital lichen sclerosus in a prospective series of 76 patients with morphea: Toward a better understanding of the spectrum of morphea. Arch Dermatol 2012;148(1):24-8
46. Kreuter A, Wischnewski J, Terras S, et al. Coexistence of lichen sclerosus and morphea: A retrospective analysis of 472 patients with localized scleroderma from a German tertiary referral center. J Am Acad Dermatol 2012;67(6):1157-62
47. Randone SB, Guiducci S, Cerinic MM. Systemic sclerosis and infections. Autoimmun Rev 2008;8(1):36-40
48. Wenzel J, Wiechert A, Merkel C, et al. IP10/CXCL10-CXCR3 interaction: A potential self-recruiting mechanism for cytotoxic lymphocytes in lichen sclerosus et atrophicus. Acta Derm Venereol 2007; 87(2):112-17
49. Fleming JN, Schwartz SM. The pathology of scleroderma vascular disease. Rheum Dis Clin North Am 2008;34(1):41-55
50. Airo P, Ghidini C, Zanotti C, et al. Upregulation of myxovirus-resistance protein A: A possible marker of type I interferon induction in systemic sclerosis. J Rheumatol 2008;35(11):2192-200
51. Tahara H, Kojima A, Hirokawa T, et al. Systemic sclerosis after interferon alphacon-1 therapy for hepatitis C. Intern Med 2007;46(8):473-6
52. Solans R, Bosch JA, Esteban I, Vilardell M. Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis. Clin Exp Rheumatol 2004;22(5):625-8
53. Airo' P, Scarsi M, Rossi M, Mondini M. Onset and enhancement of systemic sclerosis after treatments for multiple sclerosis. Rheumatol Int 2008;28(7):703-7
54. Powell A, Myles ML, Yacyshyn E. The development of systemic sclerosis in a female patient with multiple sclerosis following beta interferon treatment. Clin Rheumatol 2008;27(11):1467-8
55. Telakis E, Nikolaou A. Localized scleroderma (morphea) in a patient with chronic hepatitis C. Eur J Gastroenterol Hepatol 2009;21(4):486
56. Martinez-Garcia S, Fernandez-Ballesteros MD, Segura-Palacios JM. Vitiligo and morphea: Autoimmune cutaneous side effects of interferon treatment. Actas Dermosifiliogr 2012;103(3):250-1
57. Coelho LF, de Oliveira JG, Kroon EG. Interferons and scleroderma-A new clue to understanding the pathogenesis of sclerodermä Immunol Lett 2008;118(2): 110-15
58. Meyer O. Interferons and autoimmune disorders. Joint Bone Spine 2009;76(5): 464-73
59. Duncan MR, Berman B. Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-Term exposure to interferons. J Clin Invest 1987;79(5):1318-24
60. Brembilla NC, Chizzolini C. T cell abnormalities in systemic sclerosis with a focus on Th17 cells. Eur Cytokine Netw 2012;23(4):128-39